How to buy Aerpio Pharmaceuticals stock (ARPO)

Aerpio Pharmaceuticals is a biotechnology business based in the US. Aerpio Pharmaceuticals shares (ARPO) are listed on the NASDAQ and all prices are listed in US Dollars. Aerpio Pharmaceuticals employs 12 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Aerpio Pharmaceuticals stock

Buy Aerpio Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Aerpio Pharmaceuticals stock price (NASDAQ: ARPO)

Use our graph to track the performance of ARPO stocks over time.

Aerpio Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-10-31.

52-week range	$0.00 - $0.00
50-day moving average more info button	$31.63
200-day moving average more info button	$25.85
Wall St. target price	$22.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.41

Is it a good time to buy Aerpio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aerpio Pharmaceuticals financials

Gross profit TTM	$15 million
Return on assets TTM	-31.02%
Return on equity TTM	-47.61%
Profit margin	0%
Book value	$0.74
Market Capitalization more info button	$104.9 million

TTM: trailing 12 months

Aerpio Pharmaceuticals share dividends

We're not expecting Aerpio Pharmaceuticals to pay a dividend over the next 12 months.

Aerpio Pharmaceuticals share price volatility

Over the last 12 months, Aerpio Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerpio Pharmaceuticals's is 1.6466. This would suggest that Aerpio Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aerpio Pharmaceuticals overview

Aerpio Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease.

Frequently asked questions

null
What percentage of Aerpio Pharmaceuticals is owned by insiders or institutions?
Currently 4.274% of Aerpio Pharmaceuticals shares are held by insiders and 71.053% by institutions. How many people work for Aerpio Pharmaceuticals?
Latest data suggests 12 work at Aerpio Pharmaceuticals. When does the fiscal year end for Aerpio Pharmaceuticals?
Aerpio Pharmaceuticals's fiscal year ends in December. Where is Aerpio Pharmaceuticals based?
Aerpio Pharmaceuticals's address is: 9987 Carver Road, Cincinnati, OH, United States, 45242 What is Aerpio Pharmaceuticals's ISIN number?
Aerpio Pharmaceuticals's international securities identification number is: US00810B1052 What is Aerpio Pharmaceuticals's CUSIP number?
Aerpio Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 00810B105